Malignancy in cancer is associated with aerobic glycolysis (Warburg effect) evidenced by increased trapping of [ 18 F]deoxyglucose (FdG) in patients imaged by positron emission tomography (PET). [
Introduction
Breast cancer is the most commonly diagnosed cancer among women in the United States [1] . Thus, accurate methods for staging and diagnosis would have significant clinical benefit. Whole-body noninvasive imaging of [ 18 F]deoxyglucose uptake using positron emission tomography (FdG-PET) is considered to be the most reliable technique for the evaluation and prognosis of breast cancer [2] [3] [4] [5] [6] . FdG-PET has been shown to accurately detect and differentiate malignant from normal tissues at sensitivities of greater than 90% in breast and other cancers [7] [8] [9] [10] . Positron emission tomography imaging in breast cancer is especially precise in the detection of nodal or distant metastases [11] [12] [13] [14] [15] [16] [17] [18] [19] . However, the role of FdG-PET in the detection and diagnosis of primary breast cancer is not well established due to the limitations in detecting small-sized tumors with differentiated histologic types [14, 18, [20] [21] [22] and heterogeneous FdG uptake profiles [2, 7, 18, [20] [21] [22] [23] [24] [25] [26] [27] .
A hallmark of malignant cancers is elevated uptake of glucose even under normal oxygen conditions, known as "aerobic glycolysis" or the Warburg effect [28] . Thus, the activity of glycolysis is elevated independent of oxygen and is thus distinguished from the Pasteur effect, which describes the elevation of glycolysis in response to hypoxia. For reasons not fully understood, cells with a Warburg effect continue to catabolize glucose at a high rate, even when mitochondrial oxidative pathways are available [29] .
FdG-PET imaging does not differentiate between hypoxic (Pasteur effect) and aerobic (Warburg effect) glycolysis, but studies using combined 18-FdG and 18-F-misonidazole imaging have demonstrated that FdG avidity and hypoxia are not highly correlated in vivo [30, 31] . Elevated aerobic glycolysis is a negative prognostic indicator and may endow tumors with invasive potential and resistance to radiation and chemotherapies [32, 33] . FdG-PET imaging is used as a therapy response biomarker [34, 35] , and thus, increased knowledge regarding the regulation of deoxyglucose uptake is needed.
We have proposed that the aerobic glycolytic phenotype is established in premalignant lesions (e.g., ductal carcinoma in situ, DCIS), which grow toward ductal lumens where oxygen levels become limiting. In DCIS, the intervening basement membrane serves as a physical barrier preventing angiogenesis from relieving hypoxic stress, leading to cyclic and intermittent hypoxia in periluminal cells [36] [37] [38] [39] . This microenvironmental stress promotes the selection of cells that exhibit a phenotype with constitutive up-regulation of glycolysis [32, 40] . Explicit in our models is the concept that, because selection is based on phenotype and not genotype, multiple molecular mechanisms may be observed that would impact a common phenotype (e.g., aerobic glycolysis) [41] . One known mechanism is the stabilization of the hypoxia-inducible factor 1 alpha (HIF-1α), which will up-regulate genes necessary for maintaining tumor survival under stress, including angiogenic factors and glycolytic enzymes [42] [43] [44] . We have further proposed that, in metastases, the glycolytic phenotype persists due to increased production of glucose-derived acid, which potentiates invasiveness of cells into the extracellular matrix of the host tissue [32] .
The molecular events leading to a glycolytic phenotype in breast cancer are not well known [45] . Oncogenic factors including c-Myc [46] [47] [48] , Akt [49] , and HIF-1α [50] [51] [52] [53] [54] have been implicated in regulating aerobic glycolysis. These factors share a common prevalence in many types of cancers, are typically associated with cellular response to stress, and demonstrate pleiotropic properties, including the capacity to induce transcription of glycolytic genes. Therefore, it is reasonable to hypothesize that evolving cells constitutively upregulate one or more of these factors to establish the Warburg effect during carcinogenesis. Notable cross talk exists between these systems, viz, phosphorylated Akt (pAkt) can stimulate HIF-1α and HIF-1α can inhibit the transactivation activity of c-Myc [55] .
We have previously shown that HIF-1α was responsible for the Warburg effect in established breast and renal cancer cell lines [52] . In the current work, we extend these analyses to a panel of low-passage breast cancer lines, with the assumption that these primary cells are more closely related to cells in vivo, compared to more established cell lines. This investigation cross-correlated the glucose uptake (GURs) and lactate production rates (LPRs) and the expression of glucose transporter, GLUT-1, with the expression of activated pAkt, c-Myc, and HIF-1α levels by immunoblot analysis and enzyme-linked immunosorbent assay (ELISA). The primary lines were characterized under atmospheric (160 mm Hg) oxygen. Notably, a wide range of glycolytic activities was observed across the cell lines, consistent with the variable levels of FdG uptake observed in patients. No correlations between pAkt and glucose consumption or LPRs were observed, whereas 10 of 12 cell lines showed significant correlations between glycolytic rates and phosphorylated c-Myc and HIF-1α levels, which may be interdependent. We investigated this further by treating cultured tumor cells with 2-O-tetradecanoylphorbol-13-acetate (TPA) to stimulate c-myc transactivation. Treatment up-regulated both phosphorylated c-Myc and nuclear HIF-1α expression and was accompanied by an increase in glycolysis. In addition, inhibition of HIF-1α activity with S -2-amino-3-[4′-N ,N ,-bis(2-chloroethyl)amino]phenyl propionic acid N -oxide dihydrochloride (PX-478) [56] caused a dosedependent decrease in GURs. Thus, these data support the hypothesis that either HIF-1α or c-Myc can function to induce the Warburg effect in breast cancers.
Materials and Methods

Cells and Reagents
Cell lines were obtained from the Arizona Cancer Center tumor cell repository (Table 1) . Tissue sources include surgically removed primary cancers, mostly pleural fluid efflusates and lymph node metastases, and one isolated from ascites. Tumors were placed in a sterile Petri dish and covered with M15 medium. M15 medium is composed of Leibovitz's L-15 medium containing glutamine, transferrin hydrocortisone, insulin, catalase, 2-mercaptoethanol, 10 mg/ml penicillin/ streptomycin (Sigma, St. Louis, MO), and 5% FBS. Necrotic tissue, adherent connective tissue, fat, and blood clots were removed from the tumor, and the remaining tumor tissue was transferred to a fresh Petri dish containing medium. Tumor tissue was minced into 1-to 2-cm sections using a sterile, a #10 scalpel. Tumor samples were transferred to a conical tube, and medium was added. The supernatant containing single cells and small-cell clusters was collected and placed into a new conical tube. The remaining pellet was resuspended in medium and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded, and the pellet was resuspended in a collagenase solution (250 mg/100 ml). Tumor samples were incubated from 2 hours to overnight at 37°C, checking hourly for loosened clusters with individual rounded cells. After incubation, medium was added to the top of the tube and centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, and the pellet was resuspended in fresh medium. The supernatant containing single cells and small-cell clusters was removed and placed into a new conical tube. Samples were incubated with disaggregating enzymes if large tumor sections existed. Tumor cells were qualitatively observed by optical microscopy. Debris and red blood cells were removed using BSA debris removal technique [57] . Tumor cells were seeded in tissue flasks and grown in a 37°C incubator at 5% CO 2 .
Cells were maintained with weekly feedings involving the replacement of spent medium with new nutrient-rich growth medium. Cell lines growing in log phase (80% confluent) were subcultured in new flasks in lesser numbers to induce active growth phase. The remaining cells were kept frozen in liquid nitrogen. All cells have been cultured under 10 passages. Established cell lines, MDA-mb-231 and MDA-mb-435, were obtained from the American Type Culture Collection (Rockville, MD) and maintained in Dulbecco's modified Eagle's medium/F-12 supplemented with 10% FBS.
For tumor growth, 10 7 cells were suspended in 0.1 ml of Matrigel and were injected bilaterally into mammary fat pads of 6-week-old female severe combined immunodeficient (SCID) mice at the Arizona Cancer Center Experimental Mouse Shared Service. Tumor formation was monitored and measured electronically on a weekly basis.
Glucose Uptake
Glucose-trapping experiments were carried out as previously described [52] . Briefly, cells growing in log phase were plated in 24-well plates and allowed to attach. Cultures were washed in glucose-free RPMI medium and treated with 4 μCi of [ 3 H]-2-deoxy-D-glucose in 5.56 mM D-(+)-glucose-supplemented medium for a 1-hour incubation period. Control experiments showed that [ 3 H]-2-deoxy-Dglucose uptake was linear over this period. Supernatant was sampled for liquid scintillation counting using a liquid scintillation counter (5000TD; Beckman Coulter, Inc., Brea, CA). Cells were washed and lysed with 0.1 N NaOH for 1 minute to generate extract samples for liquid scintillation counting. The remaining lysate was neutralized with 0.1 N HCl and assayed for protein concentration using Bradford reagent (Pierce, Rockford, IL). Glucose uptake rates were calculated as nmol/min per milligram protein.
Lactate Production Assay
Cells growing in 96-well plates were washed three times with glucosefree RPMI and treated with 10 mM D-(+)-glucose-supplemented, serum-free RPMI for 1 hour incubation at 37°C in a humidified 5% CO 2 atmosphere. Lactate levels were quantified using an enzymatically coupled lactic acid detection reagent (Sigma). Protein concentrations were obtained and measured as described previously. Lactate production rates were expressed as nmol/min per milligram protein.
Real-Time Quantitative Polymerase Chain Reaction
Total RNA was isolated from cell lines with a GenElute Mammalian Total RNA Miniprep Kit (Sigma) according to the manufacturer's instructions, followed by DNase treatment. Nucleic acid purity and concentration (OD 260/280 ) were measured on a μQuant universal microplate spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT). Reactions were carried out on a SmartCycler (Cephid, Foster City, CA) using a SYBR Green reverse transcription-polymerase chain reaction kit (Qiagen, Valencia, CA). Primers amplifying the human gene products were as follows: GLUT-1 (forward -TCAATGCTGAT-GATGAAC CTGCT, reverse -GGTGACACTTCACCCAC A TACA); and β-actin (forward -CCGCATCGTCACCAACTG, reverse -GGCACACGCAGC TCATTG) (Invitrogen, Carlsbad, CA). Data were normalized with the housekeeping gene, β-actin, as an internal control using the following formula: Relative gene expression = 2 [58] .
Immunoblot Analysis and Immunohistochemistry
Cell extracts were processed with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce). Whole-cell lysates were prepared for measuring membrane-bound GLUT-1 using a cell-lysing reagent (Promega, Madison, WI). Extracts at equal concentrations (40 μg) were separated electrophoretically on an 11% polyacrylamide gel and transferred to Polyscreen PDVF blotting membrane (Perkin Elmer, Boston, MA). Immunoblot analysis techniques were carried out according to a protocol provided by Cell Signaling Technology (http:// www.cellsignal.com/index.asp). Blots were probed overnight at 4°C with primary antibodies against human HIF-1α (1:250; Transduction Laboratories, Lexington, KY), phosphorylated c-Myc
(1:1000), total c-Myc (1:1000; Cell Signaling, Danvers, MA), pAkt Ser473 (1:1000), total Akt (1:1000; Cell Signaling Technology, Beverly, MA), HIF-2α (1:100, catalogue no. GTX28365; GeneTex, San Antonio, TX), GLUT-1 (1:100), actin (1:400), and nuclear lamin (1:200; Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were counterprobed with HRP-conjugated antimouse, -goat, or -rabbit polyclonal IgG (1:10,000; Santa Cruz Biotechnology) secondary antibodies for 1 hour at room temperature. Blots were incubated in chemiluminescent substrate (Amersham Pharmacia, Uppsala, Sweden) for 1 minute and imaged using a VersArray 1300B cooled charge-coupled device camera (Roper Scientific, Duluth, GA) or exposed on BioMax film (Kodak, Rochester, NY). For presentation purposes, the qualitative images used in Figure 2 were selected from multiple blots carried out in separate experiments as representative results. Raw data are available in Figure W1 . For immunohistochemistry, the tumor sections were placed immediately in ice-cold 1% formalin containing a phosphatase-inhibiting reagent (Ventana Medical Systems, Tucson, AZ), dehydrated, paraffinembedded, and stained by the Tissue Acquisition and Cellular Macromolecular Analysis Shares Service of the Arizona Cancer Center. A series of sequential 7-μm sections were cut from the center of fixed tumors, stained with eosin, and counterstained for antigens (pAkt and total Akt). Antibodies were be coupled to HRP and stained with diaminobenzidine (DAB). Images were digitized in RGB using a 1× objective on an inverted bright field microscope (Diaphot; Nikon, Melville, NY) coupled to a 12-Megapixel charge-coupled device (Photometrics, Tucson, AZ) with an 8-mm field of view, yielding a nominal resolution of 2.2 × 2.2 μm 2 .
Enzyme-Linked Immunosorbent Assay
Semiquantitative levels of nuclear HIF-1α transactivation activity were measured by TransBinding HIF-1α Assay Kit (Panomics, Redwood City, CA) according to the manufacturer's instructions. CMyc activity was measured similarly by TransAM Transcription Factor Assay Kit (Active Motif, Carlsbad, CA). Values were expressed as absorbance measurements (450 nm) normalized to protein concentrations after subtraction of negative control background absorbance.
Transcription Factor Induction and Inhibition
At 24 hours before treatment with TPA, cells seeded in 24-well assay plates were grown in serum-free RPMI. The medium was removed and replaced with RPMI containing 10% FBS and 15 nM TPA. Cells were allowed to incubate in normoxia for 2 hours with untreated controls. Cells were subsequently tested for supernatant lactate levels and harvested for protein extraction and immunoblot analysis experiments.
Anti-HIF-1α PX-478 was kindly donated by Garth Powis from the Arizona Cancer Center, Tucson, AZ. Toxicity thresholds were measured in both cell lines by crystal violet analysis (unpublished data). MDA-mb-231 cells were grown to 80% confluency then treated with nontoxic doses of PX-478 resuspended in growth medium. Cells were grown 24 hours under hypoxia (O 2 = 2%) at 37°C. Cultures were tested for GUR and harvested for protein extraction and immunoblot analysis experiments.
Statistics
All statistical calculations were determined using the analysis feature in GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego CA; http://www.graphpad.com). Linear regression was used to test whether the slope of the line deviated from the zero slope in data sets. Unpaired, two-tailed t tests were used to determine whether means were significantly different between the two data sets. Data set correlations were considered significant when P < .05.
Results
Breast Tumor Lines Exhibit Variable Rates of Glucose Uptake and Lactate Production under Normoxic Conditions
FdG-PET is generally equivocal in diagnosing and staging breast cancers because of its high variability [3, 7, 18, [20] [21] [22] [23] [24] [25] [26] [27] . To investigate the molecular basis of such variation, the glycolytic phenotypes of low-passage breast tumor lines were examined in vitro with glucose uptake, lactate production, and GLUT-1 mRNA transcript expression. Established metastatic breast cancer lines MDA-mb-231 and MDA-mb-435 were included in these studies as reference points for other published studies. The results from these experiments are summarized in Table 2 .
Specific rates of glucose trapping were determined using [ 3 H]-2-deoxy-D-glucose (2dG) in RPMI medium. The mean uptake rate was 2.3 ± 0.4 nmol/min per milligram protein with a range of 0.6 to 5.6 nmol/min per milligram protein. Four of the 12 cell lines (ACC-3199, ACC-893, ACC-2638, and ACC-2087) exhibited uptake rates comparable to both MDA-mb-231 and MDA-mb-435, whereas four other cell lines (ACC-732, ACC-1179, ACC-3133, and ACC-2925) had significantly lower rates than MDA-mb-231 (P < .05). Cell lines ACC-2715 and ACC-3171 exhibited uptake rates significantly lower than MDA-mb-231 and MDA-mb-435, whereas cell lines ACC-812 and ACC-2150 consumed glucose at a significantly higher rate than the established lines (P < .05).
Although 2dG trapping is an effective kinetic evaluation of facilitative glucose transporter and hexokinase activities, it does not measure glucose metabolism. To verify that glucose uptake resulted in metabolism, LPRs were also determined under the same conditions. The mean LPR was 9.3 ± 1.3 nmol/min per milligram protein, and the range of values was 0.6 to 16.8 nmol/min per milligram protein. Figure 1A shows that the relationship between LPR and GUR was significantly nonzero (P = .0017), with a linear correlation coefficient (r 2 ) of 0.45. There were three outliers beyond 95% confidence intervals, namely, ACC-893, ACC-3171, and ACC-3199, which produced lactate at high rates (13.7, 10.9, and 10.1 nmol/min per milligram), yet consumed glucose at relatively low rates (2.0, 1.1, and 2.2 nmol/min per milligram), respectively. When these were excluded from analysis, the linear correlation coefficient increased to 0.85, suggesting that, for the remaining cells, the lactate was derived from glucose through glycolysis.
These results show that there is a wide range of glycolytic phenotypes among the 12 primary breast tumor lines. Cell line ACC-2715 had the lowest GUR and LPR, whereas ACC-812 and ACC-2150 had highest glycolytic activity (Table 2) . Among the other cells, the dynamic ranges were approximately fourfold for both GUR and LPR. A dynamic range of 4.3-fold for glucose trapping is consistent with specific uptake values observed by FdG-PET in clinical studies with breast cancer patients [25] . Mean (SEM) of LPRs, GURs, GLUT-1 mRNA, and GLUT-3 mRNA levels (n ≥ 3).
GLUT-1 mRNA Expression in Low-Passage Breast Tumor Lines
Glucose uptake is regulated by glucose transporters expressed on the cell surface and it represents a rate-limiting step in glycolysis. The rate of uptake is controlled primarily by transporter levels, and this can be reflected by transporter mRNA expression [52, 59] . Consequently, glucose transporter mRNA expression levels were determined and quantitatively compared to the kinetic studies. Both GLUT-1 and GLUT-3 expressions were investigated, because these glucose transporters have been associated with uptake of glucose in cancers and exhibit high affinities for both glucose and FdG [60, 61] . GLUT-3 levels were low in all primary cell lines, except ACC-3133 that expressed levels exceeding that of MDA-mb-231. GLUT-3 mRNA levels showed a negative, yet insignificant, correlation to both GUR Figure 1 . Corelationships between glycolytic markers in breast tumor lines. Linear correlations in the 12 primary breast tumor lines between LPRs and GURs (P = .0173; A), GURs and GLUT-1 mRNA levels (B), GUR and GLUT-3 mRNA levels (C), LPRs and GLUT-1 mRNA levels (D), and lactate production and GLUT-3 mRNA (E).
and LPR (Figure 1, C and E ) . GLUT-1 is often overexpressed in malignant cancers and is a negative prognostic marker in breast cancer [25, [62] [63] [64] . GLUT-1 mRNA levels ranged approximately eightfold, from 3.3 to 27.5 × 10 −5 copies relative to actin mRNA. GLUT-1 levels were more linear to LPR ( Figure 1D ) than to GUR (Figure 1B ), but this analysis was not statistically significant.
Evaluation of Nuclear HIF-1α and Phosphorylated c-Myc with Aerobic Glycolysis
Hypoxia-inducible factor 1 alpha is a subcomponent of the heterodimeric HIF-1 transcription factor. It is constitutively produced in the cytoplasm but rapidly degraded by an ubiquitin-mediated system when oxygen is present. If oxygen tension becomes critically low, HIF-1α accumulates, Thr58/Ser62 , total c-Myc, HIF-1α, and lamin loading from nuclear extracts of ACC-cell lines (A). These data were correlated to activities, as measured by ELISA (B, D) and LPR (C, E).
is phosphorylated, and is translocated to the nucleus where it combines with the HIF-1β/ARNT DNA binding component [43, 44, [65] [66] [67] . Hypoxia-inducible factor 1 coordinately induces the expression of glycolytic enzymes, including the GLUT-1 glucose transporter [68] [69] [70] .
Nuclear HIF-1α expression under normoxic conditions was examined in each of the breast tumor lines by Western immunoblot analysis (Figure 2A) . The HIF-1α signal was observed in 5 of 12 primary cell lines. Band intensities were scored from 1 to 4, with 1 being weak staining (ACC-812 cells) and 4 representing high levels (ACC-3171 and ACC-3199 cells). ACC-2087 and ACC-893 cells had intermediate HIF levels (score 2). Both of the stable cell lines (MDA-mb-231 and MDA-mb-435) exhibited strong HIF-1α staining. Nuclear HIF-1α levels were also examined by ELISA. Although we observed a wide range of variability in the ELISA test, we were still able to ascertain a significant association with the Western blot data, confirming the viability of the Western blot analysis results ( Figure 2B ). Cell lines that ranked as a 4 in the Western blot analysis had significantly higher ELISA values compared to cell lines that scored 0, 1, and 2 (P = .001).
The HIF-1α status of the primary cell lines was also compared to LPRs, as shown in Figure 2C . The two primary cell lines with the highest average LPR (ACC-812 and ACC-893) were only weakly positive for HIF-1α. It may be noteworthy that these were the only two cell lines in this panel that were isolated from primary tumors and not metastases. It is possible that HIF-2α is responsible for glycolytic regulation under normoxia in these cell lines [71] . Our investigations discovered that HIF-2α was expressed in cell line ACC-812 but not in ACC-893 ( Figure 3) . All of the cell lines positive for HIF-1α staining exhibited higher LPRs compared to cells that did not express measurable levels of HIF-1α (P = .038). Somewhat surprisingly, there was no correlation between measurable HIF-1α levels and GURs. The HIF-1α-positive and -negative cells had mean ± SEM GURs of 2.62 ± 0.77 and 2.02 ± 0.49, respectively (P = .26; α = 0.05, one-sided with equal variance).
The c-Myc transcription factor has been implicated in regulating glycolysis in tumor cells through transactivation of lactate dehydrogenase A [48] , up-regulation of GLUT-1 genes [47] , and coordinate induction of all glycolytic enzymes [46] . C-Myc is regulated by phosphorylation at Thr58 and Ser62 residues, which facilitates binding to DNA and initiation of transcription [72] . Nuclear extracts from cell lines grown under normoxia were probed with antibodies against phosphorylated c-Myc Thr58/Ser62 along with total c-Myc levels ( Figure 2A Figure 2D , the findings from these analyses were similar to the HIF-1α analysis. The cell lines that ranked as a 4 in the Western blot analysis had significantly higher ELISA absorbance values than cell lines ranked as a 0, 1, 2, and 3 (P = .0018).
As with the HIF-1α analysis, phosphorylated c-Myc status was compared to LPRs ( Figure 2E ). Here, we also observed a strong association between glycolytic phenotype and phosphorylated c-Myc status. 
Akt Does Not Correlate with Glycolysis
The serine/threonine kinase, Akt is activated by phospholipid binding and activation loop phosphorylation at Thr308 by PDK1 and by phosphorylation within the carboxy-terminus at Ser473 [73] . Akt has been shown to regulate glycolysis at several steps through posttranscriptional mechanisms. Akt localizes GLUT-1 to the cell surface and the maintenance of hexokinase function activity [74] . This activity has been shown to regulate aerobic glycolysis in tumor cells. For example, murine pro-B-cell lymphoid cells transformed with inducible Akt demonstrate up-regulated glucose uptake in vivo, and Akt-transformed human glioblastoma cells metabolize glucose in correlation with Akt activity in vitro [49] . Whole-cell extracts from breast tumor lines were analyzed for the expression of activated Ser473 pAkt [73] (Figure 4A ) by the same methods used previously for the c-Myc analysis. Total Akt was observed in all breast tumor lines. Phosphorylated Akt levels were observed in all cell lines except ACC-3199, ACC-2648, and ACC-732. Cell lines ACC-2925, ACC-2150, and ACC-893 expressed the highest intensities of Akt Ser473 . The ratio of mean band intensities between pAkt and total Akt was determined using the measure function in the ImageJ downloadable application [75] .
Expression of pAkt as a ratio to total Akt was compared to LPRs in each cell line ( Figure 4B) . A linear regression analysis determined that there was no significant deviation from zero in this comparison (P = .87). We conclude that transactivation of Akt is not necessary to regulate aerobic glycolysis in breast cancer cells and its activity-in particular reference to cell line ACC-2925-does not seem to enhance cellular glycolysis under normoxic conditions.
Pharmacologic Manipulation of c-Myc and HIF-1α
ACC-3199 cells were cultured overnight in serum-free medium to reduce activated c-Myc levels. Cultures were then treated with TPA, a reagent that acutely activates c-Myc through kinase C-mediated phosphorylation [76] . 2-O-Tetradecanoylphorbol-13-acetate caused a nearly twofold increase in lactate production after a 2-hour incubation (P = .004) along with a corresponding increase in c-Myc Figure 5 ). The blots were stripped with 0.2 M NaOH and gentle shaking for 10 minutes and were reprobed for HIF-1α. The process was repeated for nuclear lamin A/C loading control. Notably, HIF-1α expression was present under both conditions, and levels were relatively unchanged by TPA treatment ( Figure 5 ). These results suggest two possible mechanisms of glycolytic upregulation induced by TPA treatment. Activity of phospho-c-Myc induced by TPA may have directly increased glycolytic activity in ACC-3199 cells. Alternatively, a regulatory dynamic relationship between c-Myc and HIF-1 may exist.
levels (
To further test this relationship, inhibition of HIF-1α was accomplished with PX-478, a reagent that targets HIF-1α, possibly through mRNA stability [56] . MDA-mb-231 cells were cultured under hypoxic conditions (O 2 = 2%) for 24 hours to maximally up-regulate HIF-1α expression and treated with 20 and 40 mg/ml of PX-478. Both GUR and HIF-1α coordinately and significantly decreased in a dose-dependent manner ( Figure 6 ).
Tumor Formation
As a final test to characterize the phenotypes exhibited by this panel of cell lines, each cell line was inoculated bilaterally into mammary fat pads of two female SCID mice (four inocula per cell line) to test their ability to grow as tumors. Of 12 cell lines, only 4 formed tumors: ACC-3199, ACC-3171, ACC-2150, and ACC-893. This observation is consistent with other reports discussing investigations working with primary breast cancer cell lines in animals [77] . To establish a stable cell line without genetic drift as seen typically in low-passage cell lines, the tumors that grew were reimplanted twice into more SCID mice for a total of three passages. ACC-2150 and ACC-893 failed to grow after reimplantation. Hence, only ACC-3199 and ACC-3171 were able to grow reproducibly as tumors in SCID mice. Notably, their pAkt status did not change during growth: i.e. ACC-3199 remained pAkt-negative, whereas ACC-3171 was strongly pAkt-positive (Figure 7) . Both of these cell lines were positive for phospho-c-Myc and HIF-1α, and these molecular phenotypes also did not change during in vivo selection (data not shown).
Discussion
Whereas FdG uptake is uniformly high in aggressive and metastatic cancers, its use as a pathodiagnostic agent in breast cancer is limited to its high variability. The purpose of these studies was to investigate the molecular mechanisms underlying FdG uptake variability. In this study, we examined glycolytic phenotypes and the possible relationships between aerobic glycolysis and expression of oncogenic factors associated with malignancy. This investigation focused on 12 low-passage breast tumor lines and included two established metastatic breast tumor lines for comparison. Both glucose uptake and lactic acid production were variable, but highly correlated, among the individual cell lines. This is consistent with the observed variability of FdG uptake by PET scanning in breast cancer patients [2, 7, 18, [20] [21] [22] [23] [24] [25] [26] [27] . Breast carcinomas with higher rates of FdG uptake have the poorest prognosis [2] [3] [4] [5] .
Elevated FdG uptake may be associated with the Warburg effect. The relationship between the Warburg effect and malignancy suggests a possible selective advantage to cancer cells, but a proliferative advantage is not apparent. Glycolysis is energetically less efficient than oxidative phosphorylation and produces toxic byproducts. Selection of the Warburg effect for purposes of energetic fitness is not logical considering that aerobic glycolysis is an existing metabolic function in all eukaryotic cells. It must be considered, therefore, that aerobic glycolysis is not selected for production of ATP. A relatively minor fraction (<30%) of a cancer cell's aerobic ATP production is derived from glycolysis according to mass balance analyses [78] .
There are explanations, other than bioenergetics, which address this observation. Glycolysis produces hydrogen ions, and increased acidity offers a selective advantage to invading tumor cells. Alternatively, Glucose metabolism may occur through the pentose phosphate pathway, providing anabolic substrates such as ribose for nucleic acid synthesis as well as reducing equivalents (NADPH) to combat reactive oxygen species [79, 80] . This material is discussed in greater detail in a recent review by Gillies and Gatenby [81] .
In most of the cell lines, GUR correlated to LPR, indicating that either measurement would reflect rates of glucose metabolism for almost all cells. Outliers in this analysis were ACC-893, ACC-3171, and ACC-3199, which all produced lactate at rates higher than would be expected from their GURs. Interestingly, these three cell lines were also tumorigenic in SCID mice. High rates of lactate production by these cells may be due to additional lactate-producing pathways such as enhanced glutaminolysis [82] , and this remains to be confirmed. The cell line ACC-812 exhibited the highest rate of glycolysis by either measurement yet had lower than expected levels of both HIF-1α and cMyc (Figure 2 ). These cells were isolated from primary tumor sites compared to the others that were isolated from lymph nodes or pleural effusions. ACC-812 cells were also not tumorigenic in SCID mice.
Glucose transporter levels are a common end point in cancer studies due to high expression in tumor malignancy and its positive correlation with FdG-PET studies [25, 64] . In previous studies with established breast tumor lines, others and we have noted that GLUT-1 mRNA expression can reflect GLUT-1 protein expression [52, 59 ], yet these results can not be extrapolated to the current study. This could be due to a combination of several factors. Although there is evidence supporting a correlation between mRNA and protein expression [83] , there may be unknown posttranscriptional modifications or protein half-lives that would not be reflective of the true level of active glucose transporters when making comparisons to transcript levels. This phenomenon has been observed in cultured cells with disrupted oxidative phosphorylation [84] . This was noted in our own experiments as well. For example, cell lines ACC-1179, ACC-893, and ACC-3199 expressed comparably higher levels of GLUT-1 message but exhibited weak GLUT-1 protein expression ( Figure W1 ). GLUT-3 could also contribute to GUR, and it is highly expressed in the stable cell lines MDA-mb-231 and MDA-mb-435. However, in the current panel, there is no significant relationship between expression of this gene and either GUR or LPR (Figure 1 ).
Both aerobic glycolysis and GLUT-1 levels may be stimulated by a host of oncogenic factors, such as HIF-1α [50] [51] [52] [53] [54] , c-Myc [47, 48] , Neoplasia Vol. 10, No. 8, 2008 Aerobic Glycolysis in Breast Cancer Robey et al.
or Akt [49] . We noted that earlier reports have shown HIF-1α levels, measured with histologic diagnosis, did not correlate well with increased FdG uptake measured by PET in breast cancers [25] . Hence, we were concerned that the relationship between HIF-1α and the Warburg effect was particular to cell lines that were established in culture. To examine this, we developed a series of low-passage breast cancer lines, with the rationale that they would more adequately represent cells from in vivo tumors. We observed that cell lines exhibiting the highest relative rates of aerobic glycolysis were positive for nuclear HIF-1α. Notably, cell lines with lowest glycolytic rates were negative for the expression of nuclear HIF-1α. Clear exceptions to these observations are cell lines ACC-812 and ACC-893, both of which were highly glycolytic but expressed low or negative levels of normoxic HIF-1α.
Although it does not seem that HIF-1α is involved in glycolytic regulation of these two cell lines, it is possible that HIF-1 homologues such as HIF-2α may be up-regulated in these cells [71] and contribute to glycolytic regulation under normoxia. We tested for the expression of this factor in ACC-812 and ACC-893 and discovered that the expression of HIF-2α was indeed positive and comparable to a nuclear extract from metastatic breast tumor line (MDA-mb-435) that had been cultured under hypoxic conditions (O 2 at 2% for 24 hours). We did not observe any expression of HIF-2α in ACC-893 ( Figure 3 ). Another possibility for the Warburg effect in these cell lines-and this remains to be tested-is the regulation by a cell cycle regulator ubiquitin ligase with the F-box protein Grr1 (SCF Grr1 ), which has been shown to target transcription factors involved in regulating glycolysis [85] .
It was previously reported that transactivation of c-Myc is dependent on its phosphorylation at Thr58 and Ser62 [72] . This event is somewhat complicated in that phosphorylation of c-Myc at Ser62 promotes stabilization and accumulation of c-Myc and conversely, phosphorylation of c-Myc at Thr58 accelerates c-Myc ubiquitination and proteolytic degradation [86] . Dephosphorylation of Ser62 is required, however, for degradation to occur [87] . We examined the expression of c-Myc Thr58/Ser62 and observed a general correspondence with aerobic glycolysis in the primary breast tumor lines. These data corresponded with the ELISA experiments that measured c-Myc binding to an immobilized oligonucleotide containing the c-Myc consensus binding site (5′-CACGTG-3′; Figure 2D ), thus we interpret c-Myc Thr58/Ser62 expression to indicate c-Myc activity. There was a higher expression of c-Myc Thr58/Ser62 in glycolytic lines ACC-3199, ACC-3171, and ACC-2087, which were comparable to the stable cell lines MDA-mb-231 and MDA-mb-435. We also noted lower or negative c-Myc activity in cells with lowest glycolytic rates. Similar to HIF-1α, cell lines 812 and 893 expressed low levels of phosphorylated c-Myc but had the highest LPRs, suggesting that other factors are responsible for regulating glucose metabolism in these cell lines.
We also examined pAkt expression in this panel. Phosphorylated Akt expression was examined along with total Akt levels relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a common cytoplasmic protein loading control. GAPDH expression was robust in all cell lines but variable. This may be due to the role of GAPDH in glycolysis. Therefore, the levels of pAkt expression in cells were also expressed as a ratio between pAkt and total Akt from the band intensities in the Western blot ( Figure 4A ). Both pAkt/total Akt and pAkt/ GAPDH ratios were compared to lactate production and showed no significant relationship.
At the outset of these studies, cross talk between c-Myc and HIF-1 had not previously been seen. We began to examine this in more detail when it was reported in two systems by Semenza and Dang [55, 88] . To test the hypothesis that c-Myc and HIF-1α can regulate the glycolytic phenotype in breast cancer cells, c-Myc was activated with TPA. 2-O-Tetradecanoylphorbol-13-acetate induced both phosphorylated c-Myc along with a significant increase in lactate production. Effects of TPA on c-Myc phosphorylation are consistent with previous reports [76] . It should be noted that HIF-1α levels are also reportedly affected by TPA [89, 90] . One study [89] provided evidence that phorbol-12-myristate-13-acetate induced HIF-1 through mitogen-activated protein/extracellular signal-regulated kinase 1 (MEK-1) signaling. Transcription factor c-Myc can activate the MEK-1 pathway, at least in rhabdomyosarcoma cells [91] . To test if inhibition of these transcription factors would down-regulate glycolysis, HIF-1α was inhibited with PX-478 [56] , and this led to dosedependent decreases in both HIF-1α and glucose uptake. Hence, we conclude that the Warburg effect in these cell lines is also associated with elevated HIF-1α levels and that the effect is amplified by c-Myc. Because this does not explain the lack of correlation observed in vivo, we also conclude that in vivo FdG uptake can be driven by other pathways in addition to HIF-1α.
We have recently developed a model to explain why cancers have high glycolysis [32] . This model predicts that expression of a glycolytic phenotype is essential to cancer progression and predicts that this can be achieved through multiple mechanisms that can be different even within specific types of cancers. The results of this study are consistent with this prediction in that two transcription factors, cMyc and HIF-1, seem to be mutually associated with regulation of aerobic glycolysis. 
